An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children
Background Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in...
Saved in:
| Published in | BMC public health Vol. 11; no. Suppl 3; p. S30 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
13.04.2011
BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2458 1471-2458 |
| DOI | 10.1186/1471-2458-11-S3-S30 |
Cover
| Abstract | Background
Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.
Methods
We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their “collective optimism” towards each criterion was documented on a scale from 0 to 100%.
Results
In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%.
Conclusion
Although monoclonal antibodies have proven to be effective in providing protection to high-risk infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a high impact on morbidity and mortality due to severe ALRI. |
|---|---|
| AbstractList | Abstract Background: Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization. Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%. Results: In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%. Conclusion: Although monoclonal antibodies have proven to be effective in providing protection to high-risk infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a high impact on morbidity and mortality due to severe ALRI. Background Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization. Methods We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their “collective optimism” towards each criterion was documented on a scale from 0 to 100%. Results In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%. Conclusion Although monoclonal antibodies have proven to be effective in providing protection to high-risk infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a high impact on morbidity and mortality due to severe ALRI. Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.BACKGROUNDRespiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%.METHODSWe used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%.In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%.RESULTSIn the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%.Although monoclonal antibodies have proven to be effective in providing protection to high-risk infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a high impact on morbidity and mortality due to severe ALRI.CONCLUSIONAlthough monoclonal antibodies have proven to be effective in providing protection to high-risk infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a high impact on morbidity and mortality due to severe ALRI. Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization. We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%. In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%. Although monoclonal antibodies have proven to be effective in providing protection to high-risk infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a high impact on morbidity and mortality due to severe ALRI. |
| ArticleNumber | S30 |
| Author | Nair, Harish Zgaga, Lina Verma, Vasundhara R Rudan, Igor Campbell, Harry Theodoratou, Evropi Simões, Eric AF Huda, Tanvir Wright, Peter F |
| AuthorAffiliation | 4 University of Colorado Denver and The Children’s Hospital, Denver, CO, USA 6 Croatian Centre for Global Health, University of Split Medical School, Croatia 2 Public Health Foundation of India, New Delhi, India 3 International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh 1 Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh, UK 5 Division of Infectious Disease and International Health, Dartmouth Medical School, Lebanon, NH, USA |
| AuthorAffiliation_xml | – name: 4 University of Colorado Denver and The Children’s Hospital, Denver, CO, USA – name: 6 Croatian Centre for Global Health, University of Split Medical School, Croatia – name: 5 Division of Infectious Disease and International Health, Dartmouth Medical School, Lebanon, NH, USA – name: 3 International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh – name: 1 Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh, UK – name: 2 Public Health Foundation of India, New Delhi, India |
| Author_xml | – sequence: 1 givenname: Harish surname: Nair fullname: Nair, Harish organization: Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh, Public Health Foundation of India – sequence: 2 givenname: Vasundhara R surname: Verma fullname: Verma, Vasundhara R organization: Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh – sequence: 3 givenname: Evropi surname: Theodoratou fullname: Theodoratou, Evropi organization: Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh – sequence: 4 givenname: Lina surname: Zgaga fullname: Zgaga, Lina organization: Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh – sequence: 5 givenname: Tanvir surname: Huda fullname: Huda, Tanvir organization: International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) – sequence: 6 givenname: Eric AF surname: Simões fullname: Simões, Eric AF organization: University of Colorado Denver and The Children’s Hospital – sequence: 7 givenname: Peter F surname: Wright fullname: Wright, Peter F organization: Division of Infectious Disease and International Health, Dartmouth Medical School – sequence: 8 givenname: Igor surname: Rudan fullname: Rudan, Igor organization: Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh, Croatian Centre for Global Health, University of Split Medical School – sequence: 9 givenname: Harry surname: Campbell fullname: Campbell, Harry email: Harry.Campbell@ed.ac.uk organization: Centre for Population Health Sciences, Global Health Academy, The University of Edinburgh |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21501449$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ul1rFDEUHaRiP_QXCBJ8sT6M5k4yH3kRSqlaKAhd7WvIZO7MZplN1iSzsr_Cv2y229ZtHwqBm9x7zuFwc46zA-ssZtlboJ8Amuoz8BrygpdNDpDPWDr0RXb00D3Yux9mxyEsKIW6KYtX2WEBJQXOxVH298wSXKtxUtE4S1xP4hwJLtEPxg7E2Ih-jXY7DEQNytgQyTWGlfEqOr8hs43Vm2jUSG6MnwI5vZ7dfMxVCE4bFbEjSk8Ryej-oCd-j2hsj3qnayzRczN2Hu3r7GWvxoBv7upJ9uvrxc_z7_nVj2-X52dXuS55EfO-LGhPy0qXGnhfpJrana6BIutEwyuFFUVRU1YxoduGNUXDWtbqjvc17zQ7yS53up1TC7nyZqn8Rjpl5G3D-UEqH40eUSIHVZctx5ZXXPO-qZHqWkDZVp1iqk9aX3Zaq6ldYqfTurwaH4k-nlgzl4NbS1YwEJQngQ93At79njBEuTRB4zgqi24Ksqk4CADRJOT7J8iFm7xNm5KCFiAE8DKB3u37eTBy_-sJIHYA7V0IHnupTbwNQLJnRglUbhMmt_mR2_ykp5yxdGjisifce_nnWXzHCgltB_T_fT9H-wdQxOdR |
| CitedBy_id | crossref_primary_10_1128_JCM_01131_11 crossref_primary_10_1155_2013_359683 crossref_primary_10_1097_ACI_0b013e3283520fda crossref_primary_10_1016_j_vaccine_2017_04_008 crossref_primary_10_1155_2020_8919534 crossref_primary_10_1586_14760584_2014_878653 crossref_primary_10_7189_jogh_01_010304 crossref_primary_10_1038_bmt_2012_134 crossref_primary_10_1177_2515135520981516 crossref_primary_10_1586_erp_12_45 crossref_primary_10_1007_s41061_017_0129_4 crossref_primary_10_1111_irv_12313 crossref_primary_10_1016_S0140_6736_14_60691_7 crossref_primary_10_1097_INF_0b013e31825cb985 crossref_primary_10_1002_jmv_23330 crossref_primary_10_1186_s12879_024_09229_9 crossref_primary_10_1093_infdis_jit479 crossref_primary_10_1016_j_vaccine_2018_02_014 crossref_primary_10_1093_infdis_jit517 crossref_primary_10_1186_1471_2334_13_434 crossref_primary_10_7189_jogh_05_020419 crossref_primary_10_1111_irv_13282 crossref_primary_10_1136_archdischild_2020_319472 crossref_primary_10_1111_irv_13344 crossref_primary_10_1016_j_jinf_2013_11_005 crossref_primary_10_1371_journal_pone_0150416 crossref_primary_10_1155_2014_850831 crossref_primary_10_1016_S1473_3099_17_30238_4 crossref_primary_10_1093_tropej_fmac091 crossref_primary_10_1126_sciadv_abd6421 crossref_primary_10_1002_ppul_22877 crossref_primary_10_1016_j_jpedp_2017_02_014 crossref_primary_10_1097_INF_0000000000004682 crossref_primary_10_3892_mmr_2018_9089 crossref_primary_10_1128_JVI_00256_14 crossref_primary_10_1016_j_prrv_2015_08_004 crossref_primary_10_1155_2012_646780 crossref_primary_10_1093_cid_ciu095 crossref_primary_10_1186_1471_2458_13_S3_S14 crossref_primary_10_7189_jogh_07_011001 crossref_primary_10_1016_j_vaccine_2016_08_053 crossref_primary_10_1093_jpids_piaa107 crossref_primary_10_1186_s12879_020_4882_6 crossref_primary_10_1016_j_ajic_2014_04_014 crossref_primary_10_1016_j_jped_2016_11_006 crossref_primary_10_7189_jogh_06_020901 crossref_primary_10_1089_vim_2017_0098 |
| Cites_doi | 10.1371/journal.pmed.1000041 10.1046/j.1442-200X.2002.01613.x 10.1016/S0264-410X(03)00346-3 10.1016/S0140-6736(05)67599-X 10.1001/archpedi.155.1.95 10.1513/pats.200501-011AW 10.1542/peds.112.2.285 10.1097/INF.0b013e31819588d7 10.1016/S0264-410X(03)00332-3 10.1016/j.vaccine.2009.01.041 10.1093/infdis/166.4.769 10.2471/BLT.08.054353 10.1016/S0140-6736(09)61910-3 10.1016/S0140-6736(08)60560-7 10.1017/S0950268807000015 10.1016/S1473-3099(06)70687-9 10.1542/peds.102.3.531 10.1046/j.1365-3156.1998.00213.x 10.1016/S0140-6736(98)10321-5 10.1086/499600 10.1016/S0022-3476(81)80829-3 10.1016/S0140-6736(04)17145-6 10.1016/j.cimid.2007.07.008 10.1086/315859 10.1016/0264-410X(90)90141-8 10.1186/rr187 10.1016/j.jaci.2008.10.043 10.1542/peds.2008-1036 10.1046/j.1440-1754.2001.0720f.x 10.1016/j.vaccine.2008.09.018 10.1097/00006454-200204000-00006 10.3325/cmj.2008.49.720 10.1542/peds.99.1.93 10.1097/01.qco.0000224822.65599.5b 10.1056/NEJM199311183292102 10.1128/JVI.80.3.1130-1139.2006 10.1371/journal.pmed.0040259 10.1164/rccm.200406-730OC 10.1016/S0264-410X(01)00388-7 10.1016/j.jaci.2008.11.033 10.1128/JVI.78.11.6043-6047.2004 10.3325/cmj.2008.3.307 10.1111/j.1651-2227.2003.tb00582.x 10.1016/S0140-6736(10)60206-1 10.1086/427813 10.1016/j.bbrc.2010.03.144 10.1002/jmv.10148 10.1128/JVI.01709-09 10.1016/j.vaccine.2006.03.057 10.1086/322971 10.1089/vim.2005.18.255 10.1016/S0140-6736(04)17279-6 10.1038/nrd3075 10.1097/INF.0b013e318199c3b1 10.1128/JVI.01351-07 10.1016/j.cll.2009.07.004 10.1016/S0264-410X(03)00352-9 10.4161/hv.9131 10.1016/j.jaci.2010.05.026 10.1001/archpedi.156.10.1034 10.1023/A:1025384819575 10.1016/j.vaccine.2010.03.032 |
| ContentType | Journal Article |
| Copyright | Nair et al; licensee BioMed Central Ltd. 2011 This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 2011 Nair et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2011 Nair et al; licensee BioMed Central Ltd. 2011 Nair et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Nair et al; licensee BioMed Central Ltd. 2011 This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: 2011 Nair et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2011 Nair et al; licensee BioMed Central Ltd. 2011 Nair et al; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T2 7X7 7XB 88E 8C1 8FE 8FG 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA AN0 ATCPS AZQEC BENPR BGLVJ BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. L6V M0S M1P M7S PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY 7X8 5PM DOA |
| DOI | 10.1186/1471-2458-11-S3-S30 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest SciTech Collection ProQuest Technology Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Materials Science & Engineering ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest British Nursing Database Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection ProQuest Health & Medical Collection Medical Database Engineering Database Environmental Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection ProQuest Environmental Science Collection (NC LIVE) MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection ProQuest Engineering Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Engineering Database ProQuest Public Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Materials Science & Engineering Collection Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Open Access url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1471-2458 |
| EndPage | S30 |
| ExternalDocumentID | oai_doaj_org_article_e41a75b4eb464c4f87e0c7915b6da3af PMC3231904 2503067741 21501449 10_1186_1471_2458_11_S3_S30 |
| Genre | Review Evaluation Studies Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 2XV 4.4 44B 53G 5VS 6J9 6PF 7X7 7XC 88E 8C1 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAWTL ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BNQBC BPHCQ BVXVI C1A C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 L6V M1P M48 M7S M~E O5R O5S OK1 OVT P2P PATMY PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PUEGO PYCSY RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM 7T2 7XB 8FK AZQEC C1K DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c542t-f520f056c5c14f26c5542dc710e3d9846ae60e9703639cb838283b3bcd4f74dc3 |
| IEDL.DBID | M48 |
| ISSN | 1471-2458 |
| IngestDate | Wed Aug 27 01:20:11 EDT 2025 Thu Aug 21 14:06:54 EDT 2025 Mon Sep 08 11:50:07 EDT 2025 Fri Jul 25 10:44:25 EDT 2025 Wed Feb 19 01:49:51 EST 2025 Tue Jul 01 04:09:15 EDT 2025 Thu Apr 24 23:09:02 EDT 2025 Sat Sep 06 07:22:18 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 3 |
| Keywords | Candidate Vaccine Palivizumab Passive Immunization Respiratory Syncytial Virus Respiratory Syncytial Virus Infection |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c542t-f520f056c5c14f26c5542dc710e3d9846ae60e9703639cb838283b3bcd4f74dc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 ObjectType-Review-4 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/902199145?pq-origsite=%requestingapplication%&accountid=15518 |
| PMID | 21501449 |
| PQID | 902199145 |
| PQPubID | 44782 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e41a75b4eb464c4f87e0c7915b6da3af pubmedcentral_primary_oai_pubmedcentral_nih_gov_3231904 proquest_miscellaneous_864191198 proquest_journals_902199145 pubmed_primary_21501449 crossref_citationtrail_10_1186_1471_2458_11_S3_S30 crossref_primary_10_1186_1471_2458_11_S3_S30 springer_journals_10_1186_1471_2458_11_S3_S30 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-04-13 |
| PublicationDateYYYYMMDD | 2011-04-13 |
| PublicationDate_xml | – month: 04 year: 2011 text: 2011-04-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC public health |
| PublicationTitleAbbrev | BMC Public Health |
| PublicationTitleAlternate | BMC Public Health |
| PublicationYear | 2011 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | RS Tang (2966_CR43) 2008; 26 B Jones (2966_CR74) 2009; 27 H Salo (2966_CR59) 2006; 24 JT Boerma (2966_CR71) 2008; 371 I Rudan (2966_CR11) 2007; 7 S Kim (2966_CR45) 2010; 28 PL Collins (2966_CR50) 1990; 8 PE Stang (2966_CR2) 2001; 155 2966_CR75 The IMpact-RSV Study Group (2966_CR36) 1998; 102 D Farina (2966_CR68) 2002; 21 2966_CR77 2966_CR76 2966_CR34 L Kapiriri (2966_CR15) 2007; 48 RJ Singleton (2966_CR5) 2003; 112 I Rudan (2966_CR8) 2008; 49 MR Murawski (2966_CR53) 2009; 84 JE Crowe (2966_CR22) 2001; 33 PM Danzon (2966_CR58) 2003; 3 X Carbonell-Estrany (2966_CR37) 2010; 125 LE Weisman (2966_CR27) 2002; 44 JS Whitehall (2966_CR67) 2001; 37 PF Wright (2966_CR26) 2000; 182 A Roca (2966_CR30) 2002; 67 H Mok (2966_CR51) 2007; 81 JR Groothuis (2966_CR35) 1993; 329 WP Glezen (2966_CR40) 1986; 140 R Bahl (2966_CR13) 2009; 28 FM Munoz (2966_CR31) 2003; 21 PF Wright (2966_CR3) 2000 M Tomlinson (2966_CR16) 2007; 4 I Rudan (2966_CR10) 2008; 49 EA Simoes (2966_CR32) 2001; 20 P Chan (2966_CR69) 2003; 92 MW Weber (2966_CR63) 1998; 3 G Meyer (2966_CR23) 2008; 31 EA Simoes (2966_CR4) 2010; 126 M Tomlinson (2966_CR17) 2009; 87 O Fontaine (2966_CR14) 2009; 6 I Rudan (2966_CR9) 2009; 129 T Takimoto (2966_CR48) 2004; 78 CG Victora (2966_CR73) 2004; 364 S Storey (2966_CR38) 2010; 9 KH Hsu (2966_CR46) 1992; 166 LG Stensballe (2966_CR29) 2009; 123 SB Omer (2966_CR64) 2008; 136 YH Fu (2966_CR52) 2010; 395 M Tomlinson (2966_CR18) 2009; 374 RA Karron (2966_CR24) 2005; 191 2966_CR56 DR Gwatkin (2966_CR72) 2004; 364 PL Collins (2966_CR20) 2005; 2 PF Wright (2966_CR25) 2006; 193 WP Glezen (2966_CR41) 2009; 123 M Gomez (2966_CR42) 2009; 28 RT Stein (2966_CR7) 1999; 354 Y Murata (2966_CR19) 2009; 29 CM Healy (2966_CR28) 2006; 19 EA Simoes (2966_CR55) 2002; 3 CG Victora (2966_CR70) 2005; 366 I Rudan (2966_CR12) 2007; 48 DJ Nokes (2966_CR57) 2007 WP Glezen (2966_CR33) 1981; 98 2966_CR60 N Sigurs (2966_CR6) 2005; 171 2966_CR62 PE Duffy (2966_CR54) 2003; 21 S Kamal-Bahl (2966_CR66) 2002; 156 JH Schickli (2966_CR44) 2009; 5 B Greenwood (2966_CR61) 2003; 21 JR Groothuis (2966_CR78) 1993; 329 2966_CR21 2966_CR65 T Takimoto (2966_CR47) 2005; 18 PA Piedra (2966_CR39) 2003; 22 H Nair (2966_CR1) 2010; 375 L Martinez-Sobrido (2966_CR49) 2006; 80 8413475 - N Engl J Med. 1993 Nov 18;329(21):1524-30 14625999 - Int J Health Care Finance Econ. 2003 Sep;3(3):183-205 8989345 - Pediatrics. 1997 Jan;99(1):93-9 16645489 - Curr Opin Infect Dis. 2006 Jun;19(3):271-6 12850361 - Vaccine. 2003 Jul 28;21(24):3465-7 19200447 - Vaccine. 2009 Mar 13;27(12):1848-57 17760497 - PLoS Med. 2007 Aug;4(8):e259 17948946 - Croat Med J. 2007 Oct;48(5):595-604 19565122 - Bull World Health Organ. 2009 Jun;87(6):438-46 12361451 - Arch Pediatr Adolesc Med. 2002 Oct;156(10):1034-41 16414990 - J Virol. 2006 Feb;80(3):1130-9 12897275 - Pediatrics. 2003 Aug;112(2):285-90 18406860 - Lancet. 2008 Apr 12;371(9620):1259-67 12671459 - Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S94-9 19278292 - PLoS Med. 2009 Mar 10;6(3):e41 20624638 - J Allergy Clin Immunol. 2010 Aug;126(2):256-62 11738763 - Vaccine. 2001 Dec 12;20(5-6):954-60 12225544 - Pediatr Int. 2002 Oct;44(5):475-80 7229749 - J Pediatr. 1981 May;98(5):708-15 3706232 - Am J Dis Child. 1986 Jun;140(6):543-6 11547779 - J Paediatr Child Health. 2001 Aug;37(4):416-7 11177073 - Arch Pediatr Adolesc Med. 2001 Jan;155(1):95-6 2336876 - Vaccine. 1990 Apr;8(2):164-8 18581609 - Croat Med J. 2008 Jun;49(3):307-17 12116014 - J Med Virol. 2002 Aug;67(4):616-23 12801117 - Acta Paediatr. 2003 Apr;92(4):481-5 17948948 - Croat Med J. 2007 Oct;48(5):618-27 19889768 - J Virol. 2010 Jan;84(2):1110-23 20362203 - Vaccine. 2010 May 14;28(22):3801-8 17720245 - Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):191-225 16243091 - Lancet. 2005 Oct 22-28;366(9495):1460-6 15516534 - Am J Respir Crit Care Med. 2005 Jan 15;171(2):137-41 16035938 - Viral Immunol. 2005;18(2):255-66 12075758 - Pediatr Infect Dis J. 2002 Apr;21(4):287-91 18822334 - Vaccine. 2008 Nov 25;26(50):6373-82 12850355 - Vaccine. 2003 Jul 28;21(24):3436-41 16425137 - J Infect Dis. 2006 Feb 15;193(4):573-81 16678945 - Vaccine. 2006 Jun 5;24(23):4934-41 19483659 - Pediatr Infect Dis J. 2009 Jul;28(7):655-8 19121859 - J Allergy Clin Immunol. 2009 Feb;123(2):404-5 19892231 - Clin Lab Med. 2009 Dec;29(4):725-39 20399493 - Lancet. 2010 May 1;375(9725):1545-55 17182344 - Lancet Infect Dis. 2007 Jan;7(1):56-61 12119055 - Respir Res. 2002;3 Suppl 1:S26-33 15464189 - Lancet. 2004 Oct 2-8;364(9441):1273-80 16113487 - Proc Am Thorac Soc. 2005;2(2):166-73 9623927 - Trop Med Int Health. 1998 Apr;3(4):268-80 10470697 - Lancet. 1999 Aug 14;354(9178):541-5 19106763 - Pediatr Infect Dis J. 2009 Jan;28(1 Suppl):S43-8 15747245 - J Infect Dis. 2005 Apr 1;191(7):1093-104 18177515 - Epidemiol Infect. 2008 Oct;136(10):1319-27 19535827 - Indian J Med Res. 2009 Apr;129(4):351-3 19101023 - J Allergy Clin Immunol. 2009 Feb;123(2):398-403 1527411 - J Infect Dis. 1992 Oct;166(4):769-75 20350532 - Biochem Biophys Res Commun. 2010 Apr 23;395(1):87-92 20043025 - Nat Rev Drug Discov. 2010 Jan;9(1):15-6 9738173 - Pediatrics. 1998 Sep;102(3 Pt 1):531-7 19944866 - Lancet. 2009 Nov 28;374(9704):1857-62 15500901 - Lancet. 2004 Oct 23-29;364(9444):1541-8 15141002 - J Virol. 2004 Jun;78(11):6043-7 17928349 - J Virol. 2007 Dec;81(24):13710-22 11595986 - Clin Infect Dis. 2001 Nov 15;33(10):1720-7 12850339 - Vaccine. 2003 Jul 28;21(24):3358-61 20008423 - Pediatrics. 2010 Jan;125(1):e35-51 11010838 - J Infect Dis. 2000 Nov;182(5):1331-42 19556888 - Hum Vaccin. 2009 Sep;5(9):582-91 19090596 - Croat Med J. 2008 Dec;49(6):720-33 |
| References_xml | – volume: 6 start-page: e41 issue: 3 year: 2009 ident: 2966_CR14 publication-title: PLoS Med doi: 10.1371/journal.pmed.1000041 – volume: 44 start-page: 475 issue: 5 year: 2002 ident: 2966_CR27 publication-title: Pediatr Int doi: 10.1046/j.1442-200X.2002.01613.x – volume: 21 start-page: 3436 issue: 24 year: 2003 ident: 2966_CR61 publication-title: Vaccine doi: 10.1016/S0264-410X(03)00346-3 – volume: 366 start-page: 1460 issue: 9495 year: 2005 ident: 2966_CR70 publication-title: Lancet doi: 10.1016/S0140-6736(05)67599-X – volume: 155 start-page: 95 issue: 1 year: 2001 ident: 2966_CR2 publication-title: Arch Pediatr Adolesc Med doi: 10.1001/archpedi.155.1.95 – volume: 2 start-page: 166 issue: 2 year: 2005 ident: 2966_CR20 publication-title: Proc Am Thorac Soc doi: 10.1513/pats.200501-011AW – volume: 112 start-page: 285 year: 2003 ident: 2966_CR5 publication-title: Pediatrics doi: 10.1542/peds.112.2.285 – volume: 28 start-page: S43 issue: 1 Suppl year: 2009 ident: 2966_CR13 publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e31819588d7 – volume: 21 start-page: 3358 issue: 24 year: 2003 ident: 2966_CR54 publication-title: Vaccine doi: 10.1016/S0264-410X(03)00332-3 – volume: 27 start-page: 1848 issue: 12 year: 2009 ident: 2966_CR74 publication-title: Vaccine doi: 10.1016/j.vaccine.2009.01.041 – volume: 166 start-page: 769 issue: 4 year: 1992 ident: 2966_CR46 publication-title: J Infect Dis doi: 10.1093/infdis/166.4.769 – volume: 87 start-page: 438 issue: 6 year: 2009 ident: 2966_CR17 publication-title: Bull World Health Organ doi: 10.2471/BLT.08.054353 – volume: 374 start-page: 1857 issue: 9704 year: 2009 ident: 2966_CR18 publication-title: Lancet doi: 10.1016/S0140-6736(09)61910-3 – volume: 371 start-page: 1259 issue: 9620 year: 2008 ident: 2966_CR71 publication-title: Lancet doi: 10.1016/S0140-6736(08)60560-7 – volume: 136 start-page: 1319 issue: 10 year: 2008 ident: 2966_CR64 publication-title: Epidemiol Infect doi: 10.1017/S0950268807000015 – volume: 7 start-page: 56 issue: 1 year: 2007 ident: 2966_CR11 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(06)70687-9 – volume: 102 start-page: 531 issue: 3 Pt 1 year: 1998 ident: 2966_CR36 publication-title: Pediatrics doi: 10.1542/peds.102.3.531 – volume: 3 start-page: 268 issue: 4 year: 1998 ident: 2966_CR63 publication-title: Trop Med Int Health doi: 10.1046/j.1365-3156.1998.00213.x – volume: 354 start-page: 541 issue: 9178 year: 1999 ident: 2966_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(98)10321-5 – volume: 193 start-page: 573 issue: 4 year: 2006 ident: 2966_CR25 publication-title: J Infect Dis doi: 10.1086/499600 – volume: 98 start-page: 708 issue: 5 year: 1981 ident: 2966_CR33 publication-title: J Pediatr doi: 10.1016/S0022-3476(81)80829-3 – volume: 364 start-page: 1273 issue: 9441 year: 2004 ident: 2966_CR72 publication-title: Lancet doi: 10.1016/S0140-6736(04)17145-6 – volume: 31 start-page: 191 issue: 2-3 year: 2008 ident: 2966_CR23 publication-title: Comp Immunol Microbiol Infect Dis doi: 10.1016/j.cimid.2007.07.008 – ident: 2966_CR60 – volume: 182 start-page: 1331 issue: 5 year: 2000 ident: 2966_CR26 publication-title: J Infect Dis doi: 10.1086/315859 – volume: 8 start-page: 164 issue: 2 year: 1990 ident: 2966_CR50 publication-title: Vaccine doi: 10.1016/0264-410X(90)90141-8 – volume-title: Respiratory syncytial virus disease burden in the developing world year: 2007 ident: 2966_CR57 – volume: 3 start-page: S26 issue: Suppl 1 year: 2002 ident: 2966_CR55 publication-title: Respir Res doi: 10.1186/rr187 – ident: 2966_CR65 – volume: 123 start-page: 398 issue: 2 year: 2009 ident: 2966_CR29 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2008.10.043 – volume: 125 start-page: e35 issue: 1 year: 2010 ident: 2966_CR37 publication-title: Pediatrics doi: 10.1542/peds.2008-1036 – volume: 37 start-page: 416 issue: 4 year: 2001 ident: 2966_CR67 publication-title: J Paediatr Child Health doi: 10.1046/j.1440-1754.2001.0720f.x – volume: 26 start-page: 6373 issue: 50 year: 2008 ident: 2966_CR43 publication-title: Vaccine doi: 10.1016/j.vaccine.2008.09.018 – volume: 21 start-page: 287 issue: 4 year: 2002 ident: 2966_CR68 publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-200204000-00006 – ident: 2966_CR75 – volume: 49 start-page: 720 issue: 6 year: 2008 ident: 2966_CR8 publication-title: Croat Med J doi: 10.3325/cmj.2008.49.720 – ident: 2966_CR76 – ident: 2966_CR77 doi: 10.1542/peds.99.1.93 – volume: 19 start-page: 271 issue: 3 year: 2006 ident: 2966_CR28 publication-title: Curr Opin Infect Dis doi: 10.1097/01.qco.0000224822.65599.5b – volume: 329 start-page: 1524 issue: 21 year: 1993 ident: 2966_CR35 publication-title: N Engl J Med doi: 10.1056/NEJM199311183292102 – volume: 80 start-page: 1130 issue: 3 year: 2006 ident: 2966_CR49 publication-title: J Virol doi: 10.1128/JVI.80.3.1130-1139.2006 – volume: 4 start-page: e259 issue: 8 year: 2007 ident: 2966_CR16 publication-title: PLoS Med doi: 10.1371/journal.pmed.0040259 – volume: 171 start-page: 137 year: 2005 ident: 2966_CR6 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200406-730OC – volume: 20 start-page: 954 issue: 5-6 year: 2001 ident: 2966_CR32 publication-title: Vaccine doi: 10.1016/S0264-410X(01)00388-7 – volume: 123 start-page: 404 issue: 2 year: 2009 ident: 2966_CR41 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2008.11.033 – volume: 78 start-page: 6043 issue: 11 year: 2004 ident: 2966_CR48 publication-title: J Virol doi: 10.1128/JVI.78.11.6043-6047.2004 – volume: 49 start-page: 307 issue: 3 year: 2008 ident: 2966_CR10 publication-title: Croat Med J doi: 10.3325/cmj.2008.3.307 – ident: 2966_CR34 – volume: 92 start-page: 481 issue: 4 year: 2003 ident: 2966_CR69 publication-title: Acta Paediatr doi: 10.1111/j.1651-2227.2003.tb00582.x – volume: 375 start-page: 1545 issue: 9725 year: 2010 ident: 2966_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(10)60206-1 – volume: 191 start-page: 1093 issue: 7 year: 2005 ident: 2966_CR24 publication-title: J Infect Dis doi: 10.1086/427813 – volume: 395 start-page: 87 issue: 1 year: 2010 ident: 2966_CR52 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2010.03.144 – volume: 67 start-page: 616 issue: 4 year: 2002 ident: 2966_CR30 publication-title: J Med Virol doi: 10.1002/jmv.10148 – volume: 84 start-page: 1110 issue: 2 year: 2009 ident: 2966_CR53 publication-title: J Virol doi: 10.1128/JVI.01709-09 – volume: 48 start-page: 595 issue: 5 year: 2007 ident: 2966_CR12 publication-title: Croat Med J – volume: 24 start-page: 4934 issue: 23 year: 2006 ident: 2966_CR59 publication-title: Vaccine doi: 10.1016/j.vaccine.2006.03.057 – volume: 33 start-page: 1720 issue: 10 year: 2001 ident: 2966_CR22 publication-title: Clin Infect Dis doi: 10.1086/322971 – volume: 22 start-page: S94 issue: 2 Suppl year: 2003 ident: 2966_CR39 publication-title: Pediatr Infect Dis J – volume: 18 start-page: 255 issue: 2 year: 2005 ident: 2966_CR47 publication-title: Viral Immunol doi: 10.1089/vim.2005.18.255 – volume: 364 start-page: 1541 issue: 9444 year: 2004 ident: 2966_CR73 publication-title: Lancet doi: 10.1016/S0140-6736(04)17279-6 – ident: 2966_CR21 – volume: 9 start-page: 15 issue: 1 year: 2010 ident: 2966_CR38 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3075 – volume: 28 start-page: 655 issue: 7 year: 2009 ident: 2966_CR42 publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0b013e318199c3b1 – start-page: 34 volume-title: Generic protocol to examine the incidence of lower respiratory infection due to respiratory syncytial virus in children less than 5 years of age year: 2000 ident: 2966_CR3 – volume: 129 start-page: 351 issue: 4 year: 2009 ident: 2966_CR9 publication-title: Indian J Med Res – volume: 81 start-page: 13710 issue: 24 year: 2007 ident: 2966_CR51 publication-title: J Virol doi: 10.1128/JVI.01351-07 – ident: 2966_CR62 – volume: 29 start-page: 725 issue: 4 year: 2009 ident: 2966_CR19 publication-title: Clin Lab Med doi: 10.1016/j.cll.2009.07.004 – volume: 21 start-page: 3465 issue: 24 year: 2003 ident: 2966_CR31 publication-title: Vaccine doi: 10.1016/S0264-410X(03)00352-9 – volume: 5 start-page: 582 issue: 9 year: 2009 ident: 2966_CR44 publication-title: Hum Vaccin doi: 10.4161/hv.9131 – volume: 126 start-page: 256 issue: 2 year: 2010 ident: 2966_CR4 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.05.026 – volume: 140 start-page: 543 issue: 6 year: 1986 ident: 2966_CR40 publication-title: Am J Dis Child – volume: 48 start-page: 618 issue: 5 year: 2007 ident: 2966_CR15 publication-title: Croat Med J – volume: 156 start-page: 1034 issue: 10 year: 2002 ident: 2966_CR66 publication-title: Arch Pediatr Adolesc Med doi: 10.1001/archpedi.156.10.1034 – volume: 3 start-page: 183 issue: 3 year: 2003 ident: 2966_CR58 publication-title: Int J Health Care Finance Econ doi: 10.1023/A:1025384819575 – volume: 329 start-page: 1524 issue: 21 year: 1993 ident: 2966_CR78 publication-title: N Engl J Med doi: 10.1056/NEJM199311183292102 – volume: 28 start-page: 3801 issue: 22 year: 2010 ident: 2966_CR45 publication-title: Vaccine doi: 10.1016/j.vaccine.2010.03.032 – ident: 2966_CR56 – reference: 19106763 - Pediatr Infect Dis J. 2009 Jan;28(1 Suppl):S43-8 – reference: 18406860 - Lancet. 2008 Apr 12;371(9620):1259-67 – reference: 11595986 - Clin Infect Dis. 2001 Nov 15;33(10):1720-7 – reference: 12850339 - Vaccine. 2003 Jul 28;21(24):3358-61 – reference: 16414990 - J Virol. 2006 Feb;80(3):1130-9 – reference: 15464189 - Lancet. 2004 Oct 2-8;364(9441):1273-80 – reference: 8413475 - N Engl J Med. 1993 Nov 18;329(21):1524-30 – reference: 17720245 - Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):191-225 – reference: 15747245 - J Infect Dis. 2005 Apr 1;191(7):1093-104 – reference: 19483659 - Pediatr Infect Dis J. 2009 Jul;28(7):655-8 – reference: 20399493 - Lancet. 2010 May 1;375(9725):1545-55 – reference: 19200447 - Vaccine. 2009 Mar 13;27(12):1848-57 – reference: 17948948 - Croat Med J. 2007 Oct;48(5):618-27 – reference: 19121859 - J Allergy Clin Immunol. 2009 Feb;123(2):404-5 – reference: 11177073 - Arch Pediatr Adolesc Med. 2001 Jan;155(1):95-6 – reference: 20008423 - Pediatrics. 2010 Jan;125(1):e35-51 – reference: 3706232 - Am J Dis Child. 1986 Jun;140(6):543-6 – reference: 15516534 - Am J Respir Crit Care Med. 2005 Jan 15;171(2):137-41 – reference: 16678945 - Vaccine. 2006 Jun 5;24(23):4934-41 – reference: 19090596 - Croat Med J. 2008 Dec;49(6):720-33 – reference: 12850355 - Vaccine. 2003 Jul 28;21(24):3436-41 – reference: 17928349 - J Virol. 2007 Dec;81(24):13710-22 – reference: 19892231 - Clin Lab Med. 2009 Dec;29(4):725-39 – reference: 2336876 - Vaccine. 1990 Apr;8(2):164-8 – reference: 19565122 - Bull World Health Organ. 2009 Jun;87(6):438-46 – reference: 19889768 - J Virol. 2010 Jan;84(2):1110-23 – reference: 19556888 - Hum Vaccin. 2009 Sep;5(9):582-91 – reference: 12119055 - Respir Res. 2002;3 Suppl 1:S26-33 – reference: 12075758 - Pediatr Infect Dis J. 2002 Apr;21(4):287-91 – reference: 16113487 - Proc Am Thorac Soc. 2005;2(2):166-73 – reference: 16425137 - J Infect Dis. 2006 Feb 15;193(4):573-81 – reference: 19535827 - Indian J Med Res. 2009 Apr;129(4):351-3 – reference: 20624638 - J Allergy Clin Immunol. 2010 Aug;126(2):256-62 – reference: 12801117 - Acta Paediatr. 2003 Apr;92(4):481-5 – reference: 15141002 - J Virol. 2004 Jun;78(11):6043-7 – reference: 9623927 - Trop Med Int Health. 1998 Apr;3(4):268-80 – reference: 11547779 - J Paediatr Child Health. 2001 Aug;37(4):416-7 – reference: 12116014 - J Med Virol. 2002 Aug;67(4):616-23 – reference: 9738173 - Pediatrics. 1998 Sep;102(3 Pt 1):531-7 – reference: 18581609 - Croat Med J. 2008 Jun;49(3):307-17 – reference: 20350532 - Biochem Biophys Res Commun. 2010 Apr 23;395(1):87-92 – reference: 12897275 - Pediatrics. 2003 Aug;112(2):285-90 – reference: 18822334 - Vaccine. 2008 Nov 25;26(50):6373-82 – reference: 19101023 - J Allergy Clin Immunol. 2009 Feb;123(2):398-403 – reference: 17760497 - PLoS Med. 2007 Aug;4(8):e259 – reference: 17182344 - Lancet Infect Dis. 2007 Jan;7(1):56-61 – reference: 19944866 - Lancet. 2009 Nov 28;374(9704):1857-62 – reference: 17948946 - Croat Med J. 2007 Oct;48(5):595-604 – reference: 19278292 - PLoS Med. 2009 Mar 10;6(3):e41 – reference: 16243091 - Lancet. 2005 Oct 22-28;366(9495):1460-6 – reference: 20043025 - Nat Rev Drug Discov. 2010 Jan;9(1):15-6 – reference: 10470697 - Lancet. 1999 Aug 14;354(9178):541-5 – reference: 18177515 - Epidemiol Infect. 2008 Oct;136(10):1319-27 – reference: 11010838 - J Infect Dis. 2000 Nov;182(5):1331-42 – reference: 12671459 - Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S94-9 – reference: 20362203 - Vaccine. 2010 May 14;28(22):3801-8 – reference: 14625999 - Int J Health Care Finance Econ. 2003 Sep;3(3):183-205 – reference: 8989345 - Pediatrics. 1997 Jan;99(1):93-9 – reference: 12850361 - Vaccine. 2003 Jul 28;21(24):3465-7 – reference: 12361451 - Arch Pediatr Adolesc Med. 2002 Oct;156(10):1034-41 – reference: 1527411 - J Infect Dis. 1992 Oct;166(4):769-75 – reference: 12225544 - Pediatr Int. 2002 Oct;44(5):475-80 – reference: 16035938 - Viral Immunol. 2005;18(2):255-66 – reference: 16645489 - Curr Opin Infect Dis. 2006 Jun;19(3):271-6 – reference: 11738763 - Vaccine. 2001 Dec 12;20(5-6):954-60 – reference: 15500901 - Lancet. 2004 Oct 23-29;364(9444):1541-8 – reference: 7229749 - J Pediatr. 1981 May;98(5):708-15 |
| SSID | ssj0017852 |
| Score | 2.21008 |
| SecondaryResourceType | review_article |
| Snippet | Background
Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause... Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8... Abstract Background: Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause... Abstract Background Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S30 |
| SubjectTerms | Acute Disease Biostatistics Child Developing Countries Environmental Health Epidemiology Humans Immunization Immunization, Passive - economics Infants International policy LDCs Medical research Medicine Medicine & Public Health Pharmaceutical industry Public Health Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - economics Respiratory Syncytial Virus Vaccines - immunology Respiratory Syncytial Viruses - immunology Respiratory Tract Infections - prevention & control Respiratory Tract Infections - virology Streptococcus infections Studies Sustainability Vaccine Vaccines Vaccines, Attenuated - economics Vaccines, Attenuated - immunology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxUxFA7SlSBifY7VkoULBUMnk5OZZFmlpQi66LWlu5DJQwcuc-U-Fv0V_mVP5nXvVakbYWCYPIYk5yT5Th7fIeRN9JUDqyWT3jkGngumfCiZRmxf5UFBjGkd8vOX8uIKPt3Imx1XX-lMWE8P3DfcSQBuK1lDqKEEB1FVIXeV5rIuvRU2ptE31_loTA37B5XqfO1wHHpZAVINfENclSdTWLpRNhP45HtzUkfd_ze8-eexyd_2Trsp6fwReThgSXra1-GQ3AvtY_KgX4ij_f2iJ-TnaUu3lN50ESlCPpquBSf3RLTZOfO4ovabbRAv0svtBjyd3eL4i-PAnF43y82Kvr2cXb9jdhBr8NS6zTrQeXK3Rpc7GcdzXvjfpqXjrfGn5Or87OvHCzZ4YWBOQrFmURZ5RJjkpOMQC3xjsHeITILwGuGLDWUedEfkpV2tBNpwoha18xAr8E48Iwftog0vCC0dghFuY11AojDVGmItuJOFUzoUTmakGOVg3EBRnjxlzE1nqqjSJOGZJDz8NDOBT56R91OmHz1Dx93JPyQBT0kTvXYXgEpnBqUz_1K6jByN6mGGPr8yGuESom3AatApFjtr2oGxbVhsVkaVgPYx1yojz3tdmsqB0CsZtzoj1Z6W7RV0P6Ztvnd84AIbVeeQETbq47ZQd7TEy__REkfkfr_KDoyLV-RgvdyE1wjT1vVx1yN_AYnCOcU priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7SzaVQSt910xYdemihIrYl2dKhlKQkhEJC2W1CbkbWIzUsdrqPQ39F_3JHfm22LQsGY1s2smY0-qTRfAPwztvccK0EFdYYym3CqLQuowqxfR47yb0P65DnF9nZJf96La734HyIhQnbKgeb2Bpq25iwRn6ocDBCLMPF59ufNCSNCs7VIYOG7jMr2E8tw9g92EeLLOIJ7B-fXHybjm6FXIq0px5KZHaYoGWmKRcyBJfNGB7x1vDUsvj_D3r-u4PyLzdqOzqdPoKHPawkR50ePIY9Vz-BB92aHOlCjZ7C76OabNi9SeMJoj8SIoRDpiJS3dn-uCT6RlcIHcl044sns19oitEkzMlVtVgvyfvp7OoD1b2EnSXarFeOzEPmNbK48-Kw5Qu_W9VkCCB_BpenJ9-_nNE-IQM1gqcr6kUae0RMRpiE-xTPeNsaBCmOWYVIRrssdqrl9FKmlAync6xkpbHc59wa9hwmdVO7l0Ayg7gk0b5MeWAzVYr7kiVGpEYqlxoRQTrIoTA9W3lImjEv2lmLzIogvCIIDy-LGcMjjuDj-NJtR9axu_hxEPBYNDBttzeaxU3Rd9zC8UTnouSu5Bk33MvcxSZXiSgzq5n2ERwM6lH03X9ZjMoaARmfYr8Nzhhdu2a9LGTGcaqcKBnBi06XxnogCgvzXBVBvqVlWxXdflJXP1pqcIaNqmIeAR30cVOpHS3xaudPHMD9biWd04S9hslqsXZvEIqtyrd9B_sDY-I0tg priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA6ygggiut7qquTBBwWDbXOSJo_r4LII68OOu-xbSHPRgaEjc3nwV-xf3pPeZsbLglAobZOS9pyTfCcn5wshb6OvHFgtmPDOMfAFZ8oHyTRi-yoPCmJM85BnX-XpBXy5Elc9z3bKhdmN3xdKfiyw82QlCJXyv6YcD_TP7wrseZM6T-RkDBlUSpQ9rdA_Ku4NPS1D_99g5Z-rI38LkbYjz8kj8rCHjPS4k_Fjcic0h-TeWR8UPyQPuqk32mUUPSHXxw3dknjTRaQI8mhKBE4bEtHZzirHFbXf7QwRIj3fhtzp9Bf2uGj5c3o5W25W9N359PI9s70gg6fWbdaBztMGa3S5U3FY2YXvnTV0yBN_Si5OPn-bnLJ-3wXmBJRrFkWZRwRGTrgCYolnvO0dYpHAvUbAYoPMg26pu7SrFUevjde8dh5iBd7xZ-SgWTThBaHSIfwobKxLSKSlWkOseeFE6ZQOpRMZKQeRGNeTkqe9MeamdU6UNEmOJskRL82U45Fn5MNY6WfHyXF78U9J1mPRRKjd3kA9M719mgCFrUQNoQYJDqKqQu4qXYhaesttzMjRoCmmt_KV0QiQEF8DfgYdn6J5ppiLbcJiszJKAnrEhVYZed6p1dgOBFvJndUZqfYUbq-h-0-a2Y-WAZzjT9U5ZIQNqrlt1C1_4uV_lj8i97spdGAFf0UO1stNeI0YbF2_aW3vBvZFKyk priority: 102 providerName: Springer Nature |
| Title | An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children |
| URI | https://link.springer.com/article/10.1186/1471-2458-11-S3-S30 https://www.ncbi.nlm.nih.gov/pubmed/21501449 https://www.proquest.com/docview/902199145 https://www.proquest.com/docview/864191198 https://pubmed.ncbi.nlm.nih.gov/PMC3231904 https://doaj.org/article/e41a75b4eb464c4f87e0c7915b6da3af |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELfG9oKE0PhcNqj8wANIGJLYTuwHhNpqZUJiQi2dKl4ix7FHpCqFtJXYX8G_zNlJ2hXGkCJX-XDk-u6c3_ns3yH0whapZkpywgutCSsiSkRhEiIB26ehEcxaNw_56Tw5m7KPMz7bQ11W1LYDlze6di6f1LSev_n54-o9GPw7b_AieRvBAEtixoXbIzahcIAPf-ADRm4tH9uGFVLhU_BsKrQ0RP94yc6nyjP63wRD_15N-UdI1X-pRofofgsxcb_RiQdoz1QP0b1mfg43244eoV_9Cm-ZvvHCYkCC2O0WdlmLcHltKeQSq0tVAozE421cHk-uYFiG4WGOL8p6vcQvx5OLV0S10jYFVnq9MnjusrDh-lrFbvkXvLescLeZ_DGajk6_DM9Im5yBaM7iFbE8Di2gJ811xGwMv3C50ABYDC0koBplktBIz-8ldS4ouHY0p7kumE1ZoekTtF8tKnOEcKIBo0TK5jFzzKZSMpvTSPNYC2lizQMUd3LIdMtc7hJozDPvwYgkc8LLnPDgNJtQOMIAvd5U-t4Qd9z--MAJePOoY932Fxb1ZdYacWZYpFKeM5OzhGlmRWpCncqI50mhqLIBOunUI-s0OZOAogCEM_gbeHMXbNgFZlRlFutlJhIGbnMkRYCeNrq0aQcgMufzygClO1q209DdO1X5zdOEU-hUGbIAkU4ft426pSeO_9_ME3S3mVpnJKLP0P6qXpvngM1WeQ_dSWcplGIYuXL0oYcOBqfnn8dwNkyGPT_n0fNWCeV48BXKadz_Dep9PZo |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3ra9RAEB_q9YOCiG9jfewHBQWXJtndJPuhSKstV9se0mtLv8XNPurBkav3QPpX-Bf5vzmbx11P5b4VAiFPNpnZmd_M7MwAvHEm1VxJQYXRmnITMZoZm1CJ2D4Nbcad837Io17SPeVfzsX5Gvxuc2H8sspWJlaC2oy095FvSlRGiGW4-Hj5g_qmUT642nbQUE1nBbNVVRhr8joO7NVPtOAmW_ufkdxv43hv9-RTlzZNBqgWPJ5SJ-LQIQrQQkfcxbjH00aj4rXMSNTOyiahlVWdKqmLjKGJwgpWaMNdyo1m-N5bsM69_6QD6zu7va_H8zBGmom4KXUUZclmhJqAxlxkPpmtz3ALl9Rh1TXgf1D33xWbf4VtK224dx_uNTCWbNd89wDWbPkQ7tY-QFKnNj2CX9slWVQTJyNHEG0Sn5HsOyORwbXllhOiLtQAoSo5XsT-Sf8KRT-KoCE5G4xnE_LuuH_2nqqGo6whSs-mlgx9pzcyvvZgu8QM3zsoSZuw_hhOb4Q2T6BTjkr7DEiiEQdFyhUx99VTpeSuYJEWsc6kjbUIIG7pkOumOrpv0jHMKyspS3JPvNwTDw_zPsMtDODD_KHLujjI6tt3PIHnt_rK3tWJ0fgibwRFbnmkUlFwW_CEa-6y1IY6lZEoEqOYcgFstOyRN-Jmks8nRwBkfhXlhA_-qNKOZpM8Szia5pHMAnha89J8HIj6vF0tA0iXuGxpoMtXysH3qhQ5w58qQx4AbflxMagVf-L5yo94Dbe7J0eH-eF-72AD7tRefE4j9gI60_HMvkQYOC1eNZONwLebnt9_APhccK0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Za9wwEBYlgVAoJU2PuOmhhz60UBHbGtnS4_ZY0iOhZLuhb0LWkS4s3rDHQ39F_3JHPnazPQIFg7EtGdmjkb7RzHwi5EVwpQWjBBPOWgYu40w6XzCF2L5MvYQQ4jrk6VlxMoaP30QfTbjoo917l2Sb0xBZmurl8ZULrYrL4jjDIZXlIGTMChtxPNBq3wWcrGNU1zgfrB0JpRR5Rzb0j4pbE1LD2_83sPlnzORvjtNmPhruk7sdkKSDVvL3yC1fH5C9085VfkDutAtytM0zuk9-Dmq6ofams0AR-tGYHhy3KaKTa7GPC2ouzQRxIz3fOOLp6AeOwzgeTOnFZL5a0Jfno4tXzHTi9Y4au1p6Oo3brtH5tYp9vBe-d1LTPnv8ARkP3399e8K63RiYFZAvWRB5GhAuWWEzCDme8baziFA8dwphjPFF6lVD6KVsJTnacrzilXUQSnCWPyQ79az2h4QWFkFJZkKVQ6QyVQpCxTMrciuVz61ISN6LRNuOqjzumDHVjckiCx3lqKMc8VKPOB5pQl6vK121TB03F38TZb0uGmm2mxuz-aXutFZ7yEwpKvAVFGAhyNKntlSZqApnuAkJOep7iu50f6EVwiZE3YCfQddPUWmjJ8bUfrZaaFkA2smZkgl51HardTsQgkUjVyWk3OpwWw3dflJPvje84Bx_qkohIazvmptG3fAnHv9n-edk78u7of784ezTEbndrrEDy_gTsrOcr_xTBGnL6lmjhr8AIow2fg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+evaluation+of+the+emerging+interventions+against+Respiratory+Syncytial+Virus+%28RSV%29-associated+acute+lower+respiratory+infections+in+children&rft.jtitle=BMC+public+health&rft.au=Nair%2C+Harish&rft.au=Verma%2C+Vasundhara+R&rft.au=Theodoratou%2C+Evropi&rft.au=Zgaga%2C+Lina&rft.date=2011-04-13&rft.issn=1471-2458&rft.eissn=1471-2458&rft.volume=11+Suppl+3&rft.spage=S30&rft_id=info:doi/10.1186%2F1471-2458-11-S3-S30&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon |